Konference: 2005 1. ročník Dny diagnostické, prediktivní a experimentální onkologie
Kategorie: Maligní lymfomy a leukémie
Téma: Postery
Číslo abstraktu: P018
Autoři: MUDr. Lukáš Smolej, Ph.D.; Doc.RNDr. Ctirad Andrýs, Ph.D.; prof. MUDr. Luděk Pour, Ph.D.; Prof. MUDr. Pavel Žák, Ph.D.; MUDr. David Belada, Ph.D.; Doc. MUDr. Vladimír Maisnar, Ph.D.; M. Hrudková; MUDr. Jakub Novosad, Ph.D.; MUDr. Oldřich Široký; Prof. RNDr. Jan Krejsek, CSc.; MUDr. Jaroslava Voglová; Prof.MUDr. Jaroslav Malý, CSc.
Background:
Angiogenesis, i.e. development of new blood vessels from preexisting vasculature, has been recently shown to be involved in pathogenesis and progression of various hematological malignancies. Angiogenic cytokines, e.g. vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) can be detected in peripheral blood in virtually all hematological malignancies. In our study, we measured peripheral blood concentrations of VEGF and bFGF in patients with newly diagnosed untreated multiple myeloma. Comercially available sandwich enzyme- -linked immunosorbent assay (ELISA) kits were used to determine peripheral blood plasma levels of VEGF and bFGF in patients with multiple myeloma (MM, n=45), follicular lymphoma (FL, n=11), diffuse large B-cell lymphoma (DLBCL, n=15), and chronic myeloid leukemia (CML, n=9). Plasma specimens from 50 healthy donors served as the control group.
Results:
We found significant increased bFGF in MM (p<0,0001) and FL (p=0,0119) whereas VEGF was significantly elevated in MM (p=0,0386) and CML (p<0,0001). Conclusions: We detected significant elevation of peripheral blood plasma VEGF and bFGF in patients with multiple myeloma and chronic myeloid leukemia and significantly elevated bFGF (but not VEGF) in follicular lymphoma. Diffuse large B-cell lymphoma was not significantly different from controls in both investigated cytokines. Our future study will include analysis of prognostic significance on patients’ survival, especially in those who undergo high dose chemotherapy with autologous stem cell transplantation.
Acknowledgement: Supported by grants NR/ 8076-3 and NR/8373-3 from Ministry of Health, Czech Republic.
Angiogenesis, i.e. development of new blood vessels from preexisting vasculature, has been recently shown to be involved in pathogenesis and progression of various hematological malignancies. Angiogenic cytokines, e.g. vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) can be detected in peripheral blood in virtually all hematological malignancies. In our study, we measured peripheral blood concentrations of VEGF and bFGF in patients with newly diagnosed untreated multiple myeloma. Comercially available sandwich enzyme- -linked immunosorbent assay (ELISA) kits were used to determine peripheral blood plasma levels of VEGF and bFGF in patients with multiple myeloma (MM, n=45), follicular lymphoma (FL, n=11), diffuse large B-cell lymphoma (DLBCL, n=15), and chronic myeloid leukemia (CML, n=9). Plasma specimens from 50 healthy donors served as the control group.
Results:
We found significant increased bFGF in MM (p<0,0001) and FL (p=0,0119) whereas VEGF was significantly elevated in MM (p=0,0386) and CML (p<0,0001). Conclusions: We detected significant elevation of peripheral blood plasma VEGF and bFGF in patients with multiple myeloma and chronic myeloid leukemia and significantly elevated bFGF (but not VEGF) in follicular lymphoma. Diffuse large B-cell lymphoma was not significantly different from controls in both investigated cytokines. Our future study will include analysis of prognostic significance on patients’ survival, especially in those who undergo high dose chemotherapy with autologous stem cell transplantation.
Acknowledgement: Supported by grants NR/ 8076-3 and NR/8373-3 from Ministry of Health, Czech Republic.
Datum přednesení příspěvku: 10. 12. 2005
